 KT-621 BroADen Phase 1b Safety Summary

• Well-tolerated with favorable safety at both 100 mg and 200 mg with a profile
  similar to what was observed in the Phase 1a healthy volunteer trial

• No SAEs or Severe AEs

• No dose-dependent pattern in the TEAEs

• No related TEAEs or TEAEs leading to discontinuation

• No AEs of conjunctivitis (or of any ocular disorder), herpes infections, or
  arthralgias

• No clinically relevant changes in vital signs, laboratory tests or ECGs


                                                                                  34
